Struggling Arena Pharma axes 80 jobs, narrows R&D

Just a couple of weeks after booting company co-founder and CEO Jack Lief out of the company, a struggling Arena Pharmaceuticals ($ARNA) has followed up with a move to ax 35% of its staff--some 80 jobs--while narrowing its R&D focus. Arena has been losing market share with its obesity drug Belviq, which has proved to be a troublesome therapy to market. The focus at Arena now will be on "near-term" activities. Company shares are down 8% this morning. More cuts are also on the way. Release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.